Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quinazolinone-dihydropyrano[3,2-b]pyran hybrids as new α-glucosidase inhibitors: Design, synthesis, enzymatic inhibition, docking study and prediction of pharmacokinetic.
Sherafati M, Mirzazadeh R, Barzegari E, Mohammadi-Khanaposhtani M, Azizian H, Sadegh Asgari M, Hosseini S, Zabihi E, Mojtabavi S, Ali Faramarzi M, Mahdavi M, Larijani B, Rastegar H, Hamedifar H, Hamed Hajimiri M. Sherafati M, et al. Among authors: hamedifar h. Bioorg Chem. 2021 Apr;109:104703. doi: 10.1016/j.bioorg.2021.104703. Epub 2021 Feb 8. Bioorg Chem. 2021. PMID: 33609917
A new series of Schiff base derivatives bearing 1,2,3-triazole: Design, synthesis, molecular docking, and α-glucosidase inhibition.
Nasli-Esfahani E, Mohammadi-Khanaposhtani M, Rezaei S, Sarrafi Y, Sharafi Z, Samadi N, Faramarzi MA, Bandarian F, Hamedifar H, Larijani B, Hajimiri M, Mahdavi M. Nasli-Esfahani E, et al. Among authors: hamedifar h. Arch Pharm (Weinheim). 2019 Aug;352(8):e1900034. doi: 10.1002/ardp.201900034. Epub 2019 Jul 22. Arch Pharm (Weinheim). 2019. PMID: 31330079
Biscoumarin-1,2,3-triazole hybrids as novel anti-diabetic agents: Design, synthesis, in vitro α-glucosidase inhibition, kinetic, and docking studies.
Asgari MS, Mohammadi-Khanaposhtani M, Kiani M, Ranjbar PR, Zabihi E, Pourbagher R, Rahimi R, Faramarzi MA, Biglar M, Larijani B, Mahdavi M, Hamedifar H, Hajimiri MH. Asgari MS, et al. Among authors: hamedifar h. Bioorg Chem. 2019 Nov;92:103206. doi: 10.1016/j.bioorg.2019.103206. Epub 2019 Aug 16. Bioorg Chem. 2019. PMID: 31445191
Synthesis, characterization, molecular docking, and biological activities of coumarin-1,2,3-triazole-acetamide hybrid derivatives.
Sepehri N, Mohammadi-Khanaposhtani M, Asemanipoor N, Hosseini S, Biglar M, Larijani B, Mahdavi M, Hamedifar H, Taslimi P, Sadeghian N, Gulcin I. Sepehri N, et al. Among authors: hamedifar h. Arch Pharm (Weinheim). 2020 Oct;353(10):e2000109. doi: 10.1002/ardp.202000109. Epub 2020 Jul 9. Arch Pharm (Weinheim). 2020. PMID: 32643792
Novel quinazolin-sulfonamid derivatives: synthesis, characterization, biological evaluation, and molecular docking studies.
Sepehri N, Mohammadi-Khanaposhtani M, Asemanipoor N, Hosseini S, Biglar M, Larijani B, Mahdavi M, Hamedifar H, Taslimi P, Sadeghian N, Norizadehtazehkand M, Gulcin I. Sepehri N, et al. Among authors: hamedifar h. J Biomol Struct Dyn. 2022 May;40(8):3359-3370. doi: 10.1080/07391102.2020.1847193. Epub 2020 Nov 23. J Biomol Struct Dyn. 2022. PMID: 33222620
41 results